Cargando…

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension

BACKGROUND: The rs738409 C>G p.I148M variant in the patatin‐like phospholipase domain containing 3 (PNPLA3)‐gene promotes triglyceride accumulation in hepatocytes and hepatic stellate cell activation and has previously been linked to hepatic steatosis/liver fibrosis. AIM: To investigate its impac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandorfer, M., Scheiner, B., Stättermayer, A. F., Schwabl, P., Paternostro, R., Bauer, D., Schaefer, B., Zoller, H., Peck‐Radosavljevic, M., Trauner, M., Reiberger, T., Ferenci, P., Ferlitsch, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Hepatic Decompensation in Portal Hypertension
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099386/ https://www.ncbi.nlm.nih.gov/pubmed/29956823 http://dx.doi.org/10.1111/apt.14856

Ejemplares similares

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation
por: Alabsawy, Eman, et al.
Publicado: (2022)

Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension
por: Leeming, D J, et al.
Publicado: (2013)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2018)

Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2016)

Pediatric portal hypertension: A review for primary care
por: Vogel, Clarissa Barbon
Publicado: (2017)

SARC‐F combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?
por: Reiberger, Thomas, et al.
Publicado: (2018)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy
por: Mandorfer, Mattias, et al.
Publicado: (2019)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients
por: Hartl, Lukas, et al.
Publicado: (2022)

Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study
por: Jachs, Mathias, et al.
Publicado: (2022)

Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis
por: Hofer, Benedikt S., et al.
Publicado: (2022)

Hepatic encephalopathy: a critical current review
por: Hadjihambi, Anna, et al.
Publicado: (2017)

Biology of portal hypertension
por: McConnell, Matthew, et al.
Publicado: (2017)

Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population
por: Schmidbauer, Caroline, et al.
Publicado: (2020)

Implementation of a ‘care bundle’ improves the management of patients admitted to hospital with decompensated cirrhosis
por: Dyson, J. K., et al.
Publicado: (2016)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites
por: Mandorfer, Mattias, et al.
Publicado: (2014)

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study
por: Scheiner, Bernhard, et al.
Publicado: (2016)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients
por: Schmidbauer, Caroline, et al.
Publicado: (2021)

Non‐invasive diagnosis of cirrhosis and long‐term disease monitoring by transient elastography in patients with Wilson disease
por: Paternostro, Rafael, et al.
Publicado: (2020)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
por: Chromy, David, et al.
Publicado: (2017)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis
por: Arabi, Yaseen M, et al.
Publicado: (2012)

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy
por: Rockey, Don C, et al.
Publicado: (2014)

Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease
por: Hadjihambi, Anna, et al.
Publicado: (2017)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hab3qdlnas4njg76sp05b804vs